methyl 1-(5-isoquinolinylsulfonyl)piperazinepropionate | 129786-35-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: methyl 1-(5-isoquinolinylsulfonyl)piperazinepropionate
• 英文别名: Methyl 3-(4-isoquinolin-5-ylsulfonylpiperazin-1-yl)propanoate
• CAS: 129786-35-2
• 化学式: C₁₇H₂₁N₃O₄S
• 分子量: 363.437
• InChiKey: FAXAOIMDHKSUCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  88.2
• 氢给体数：
  0
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  异喹啉-5-磺酰氯 在 三乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 methyl 1-(5-isoquinolinylsulfonyl)piperazinepropionate
  参考文献：
  名称：

  Design of potent protein kinases inhibitors using the bisubstrate approach

  摘要：

  A new class of serine/threonine protein kinase inhibitors was designed by associating, in the same structure, mimics of both the ATP binding site and a protein substrate. Among the several potent antagonists which were obtained, the most active consists of isoquinoline-5-sulfonamide, as ATP mimic, and Ser-Arg6, as peptidic moiety, bound by a -NH(CH2)2NH(CH2)2CO- linker. This compound, with a K(i) of 0.1-mu-M toward protein kinase C (PKC) and 0.004-mu-M toward cyclic AMP dependent protein kinase (PKA), is respectively 60- and 750-fold more active than the commercial inhibitor H-7.

  DOI：

  10.1021/jm00105a012

文献信息

• RICOUART, A.;GESQUIERE, J. C.;TARTAR, A.;SERGHERAERT, C., J. MED. CHEM., 34,(1991) N, C. 73-78
  作者：RICOUART, A.、GESQUIERE, J. C.、TARTAR, A.、SERGHERAERT, C.

  DOI：——

  日期：——
• Design of potent protein kinases inhibitors using the bisubstrate approach
  作者：A. Ricouart、J. C. Gesquiere、A. Tartar、C. Sergheraert

  DOI：10.1021/jm00105a012

  日期：1991.1

  A new class of serine/threonine protein kinase inhibitors was designed by associating, in the same structure, mimics of both the ATP binding site and a protein substrate. Among the several potent antagonists which were obtained, the most active consists of isoquinoline-5-sulfonamide, as ATP mimic, and Ser-Arg6, as peptidic moiety, bound by a -NH(CH2)2NH(CH2)2CO- linker. This compound, with a K(i) of 0.1-mu-M toward protein kinase C (PKC) and 0.004-mu-M toward cyclic AMP dependent protein kinase (PKA), is respectively 60- and 750-fold more active than the commercial inhibitor H-7.